As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
14 Analysts have issued a InflaRx N.V. forecast:
14 Analysts have issued a InflaRx N.V. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 0.15 0.15 |
25%
25%
|
|
Gross Profit | -0.18 -0.18 |
77%
77%
|
|
EBITDA | -62 -62 |
15%
15%
|
EBIT (Operating Income) EBIT | -63 -63 |
14%
14%
|
Net Profit | -52 -52 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Head office | Netherlands |
CEO | Niels Riedemann |
Employees | 74 |
Founded | 2007 |
Website | www.inflarx.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.